This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-PSMA IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the PSMA as well as the biological activity of IL2. This antibody-cytokine fusion protein is an C-terminus interleukin-2 (IL2)-fused immunocytokine, exhibited enhanced cytotoxic activity against PSMA-expressing prostate cancer cells in the presence of PBMCs. It has a therapeutic potential for prostate cancer by stimulating lymphocyte-mediated antitumor cytotoxicity. This immunocytokine was designed for treating prostate cancer.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
NABG-066 | Recombinant Anti-Human FOLH1 VHH Single Domain Antibody | ELISA, IHC, FC, FuncS | Llama VHH |
TAB-277CT | Anti-Human PSMA Single Domain Antibody (TAB-277CT), Research Grade Biosimilar | ELISA | Single domain antibody |
HPAB-M0386-YC | Recombinant Camelid Anti-FOLH1 Single Domain Antibody (HPAB-M0386-YC) | ELISA | Camelid VHH |
There are currently no Customer reviews or questions for ACFP-SH007. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.